PreludeDx™ to Present Data in DCIS and Stage I, II Early Breast Cancer at the 2024 Miami Breast Cancer Conference

LAGUNA HILLS, Calif., February 22, 2024 /PRNewswire/-- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced that data will be highlighted in three separate poster presentations at the 2024 Miami Breast Cancer Conference (MBCC), held on March 7 – 10, 2024 at the Fontainebleau, Miami Beach, FL.

"We are excited to share data regarding our novel biosignature for invasive Stage I, II breast cancer test for radiation therapy, as well as clinical utility data on our DCISionRT test for DCIS at the prestigious MBCC conference," said Dan Forche, President and CEO of PreludeDx. "We look forward to connecting with colleagues and sharing our vision for future early-stage breast cancer products, as well as advancing collaboration opportunities."

PreludeDx MBCC Posters to Be Presented

Title: *A Novel Biosignature for Early-Stage Invasive Breast Cancer to Predict Radiotherapy Benefit and Assess Recurrence Risk for Patients Treated with Breast-Conserving Surgery*
Presenter: Troy Bremer, PhD, Chief Scientific Officer, PreludeDx
Date: Thursday, March 7, 5:30 – 6:30 p.m. and Friday, March 8, 4:45 – 6:00 p.m. ET

Title: *Impact on Radiation Therapy Recommendation and Treatment Modality for Patients with Ductal Carcinoma in Situ Using the 7-Gene Biosignature: Analysis of the PREDICT Study*
Presenter: Chirag S. Shah, MD, Co-Director of Breast Radiation Oncology, Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
Date: Thursday, March 7, 5:30 – 6:30 p.m. and Friday, March 8, 4:45 – 6:00 p.m. ET

Title: *Limitations in the Application of Clinicopathologic Factors Alone in Predicting Radiation Benefit for Women with Low-Risk DCIS after Breast Conserving Surgery: The Impact of a 7-Gene Biosignature Based on 10-year Ipsilateral Breast Recurrence (IBR) Rates*
Presenter: Frank A. Vicini, MD, FASTRO, Radiation Oncologist at Michigan HealthCare Professionals, member of NRG Oncology
Date: Thursday, March 7, 5:30 – 6:30 p.m. and Friday, March 8, 4:45 – 6:00 p.m. ET

About DCISionRT for Breast DCIS

DCISionRT is the *only* risk assessment test for patients with ductal carcinoma in situ (DCIS) that predicts radiation therapy benefit. Patients with DCIS have cancerous cells lining the milk ducts of the breast, but they have not spread into surrounding breast tissue. In the US, over 60,000 women are newly diagnosed with DCIS each year. DCISionRT, developed by PreludeDx on technology licensed from the University of California San Francisco, and built on research that began with funding from the National Cancer Institute, enables physicians to better understand the biology of DCIS. DCISionRT combines the latest innovations in molecular biology with risk-based assessment scores to assess a woman's individual tumor biology along with other pathologic risk factors and provide a personalized recurrence risk. The test provides a Decision Score™ that identifies a woman's risk as low or elevated. Unlike other risk assessment tools, the DCISionRT test combines protein expression from seven biomarkers and four clinicopathologic factors, using a non-linear algorithm to account for multiple interactions between individual factors in order to better interpret complex biological information. DCISionRT's intelligent reporting provides a woman's recurrence risk after breast conserving surgery alone and with the addition of radiation therapy. In turn, this new information may help patients and their physicians to make more informed treatment decisions.

About PreludeDx

PreludeDx is a leading personalized breast cancer diagnostics company dedicated to serving breast cancer patients and physicians worldwide. Founded in 2009 with technology licensed from University of California San Francisco, PreludeDx has focused on developing precision breast cancer tools that will impact a patient's treatment decision. Our mission is to provide patients and physicians with innovative technologies that improve patient outcomes and reduce the overall cost burden to the healthcare system. Before making a treatment decision, Know Your Risk™. PreludeDx is a Fjord Ventures portfolio company.

For more information on how PreludeDx is making a difference for patients, please visit the Company's website: https://preludedx.com and follow us on Twitter @PreludeDx, Facebook, Instagram and LinkedIn.

PreludeDx, the PreludeDx logo, DCISionRT, the DCISionRT logo, DecisionTree, Decision Score, The DCIS Test, Know Your Risk and Your Biology, Your Decision are trademarks of Prelude Corporation or its wholly owned subsidiaries in the United States and foreign countries.

Media Contact	**Investor Contact**
Cory Dunn	Andrew Wade
760.705.7464	949.600.8925
cdunn@preludedx.com	awade@preludedx.com